Personalizing Cancer Treatment of Combined Targeting of PI3K/AKT and RAS/MEK Pathways in Advanced Cancer Patients: From the Start Phase I Clinical Trial Program

MLA

M. Beeram, et al. “Personalizing Cancer Treatment of Combined Targeting of PI3K/AKT and RAS/MEK Pathways in Advanced Cancer Patients: From the Start Phase I Clinical Trial Program.” Annals of Oncology, vol. 23, Oct. 2012, p. xi27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5381b37c4fd3f53d783a185e2b225b9e&authtype=sso&custid=ns315887.

APA

M. Beeram, Toshio Shimizu, Amita Patnaik, Brianne Kaiser, Lon Smith, M.J. Wick, Kyri Papadopoulos, Drew W. Rasco, Ronald L. Drengler, Anthony W. Tolcher, Theresa Mays, Leslie Smetzer, & Shelly Gunn. (2012). Personalizing Cancer Treatment of Combined Targeting of PI3K/AKT and RAS/MEK Pathways in Advanced Cancer Patients: From the Start Phase I Clinical Trial Program. Annals of Oncology, 23, xi27.

Chicago

M. Beeram, Toshio Shimizu, Amita Patnaik, Brianne Kaiser, Lon Smith, M.J. Wick, Kyri Papadopoulos, et al. 2012. “Personalizing Cancer Treatment of Combined Targeting of PI3K/AKT and RAS/MEK Pathways in Advanced Cancer Patients: From the Start Phase I Clinical Trial Program.” Annals of Oncology 23 (October): xi27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5381b37c4fd3f53d783a185e2b225b9e&authtype=sso&custid=ns315887.